Upland Panviva Now Available on Genesys AppFoundry
Panviva and Genesys Customer Experience Platform offering to deliver omnichannel knowledge for highly regulated industries…
Month: August 2023
Published Analysis of Sotagliflozin (INPEFA(TM)) Clinical Data Demonstrates Significant Reductions in the Risk of Hospital Readmissions for Heart Failure
Post-Hoc Analysis of SOLOIST-WHF Clinical Data Published in Journal of the American College of Cardiology:…
Published Analysis of Sotagliflozin (INPEFA(TM)) Clinical Data Demonstrates Significant Reductions in the Risk of Hospital Readmissions for Heart Failure
Post-Hoc Analysis of SOLOIST-WHF Clinical Data Published in Journal of the American College of Cardiology:…
Sofwave Medical Reports Second Quarter and First Half 2023 Financial Results and Recent Business Highlights
– Second quarter revenue of $12.4M, +53% year-over-year growth– Second quarter pulse recurring revenue of…
Sofwave Medical Reports Second Quarter and First Half 2023 Financial Results and Recent Business Highlights
– Second quarter revenue of $12.4M, +53% year-over-year growth– Second quarter pulse recurring revenue of…
Viracta Therapeutics Announces Publication in Blood Advances Demonstrating Promising and Durable Signal of Nana-val Efficacy in Patients with Relapsed or Refractory (R/R) Epstein-Barr Virus-Positive (EBV+) Lymphoma
Results from Phase 1b/2 trial showed complete responses achieved and ongoing durable responses observed out…
Viracta Therapeutics Announces Publication in Blood Advances Demonstrating Promising and Durable Signal of Nana-val Efficacy in Patients with Relapsed or Refractory (R/R) Epstein-Barr Virus-Positive (EBV+) Lymphoma
Results from Phase 1b/2 trial showed complete responses achieved and ongoing durable responses observed out…
Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent Restenosis
Virtue® Sirolimus AngioInfusion Balloon (“SAB”) is the only non-coated angioplasty system providing protected delivery of…
Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent Restenosis
Virtue® Sirolimus AngioInfusion Balloon (“SAB”) is the only non-coated angioplasty system providing protected delivery of…
Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
– Interim data readouts from ongoing Phase 1/2 trials of INZ-701 in adults with ENPP1…
Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
– Interim data readouts from ongoing Phase 1/2 trials of INZ-701 in adults with ENPP1…
PepGen Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
– Phase 2 open-label CONNECT1-EDO51 study open in Canada – – Potentially registrational, randomized, double-blind,…
PepGen Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
– Phase 2 open-label CONNECT1-EDO51 study open in Canada – – Potentially registrational, randomized, double-blind,…
AIM ImmunoTech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
Topline data expected as early as Q1 2024 OCALA, Fla., Aug. 08, 2023 (GLOBE NEWSWIRE)…
AIM ImmunoTech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
Topline data expected as early as Q1 2024 OCALA, Fla., Aug. 08, 2023 (GLOBE NEWSWIRE)…
IO Biotech Announces Abstract Accepted for Poster Presentation at ESMO Congress 2023
NEW YORK, Aug. 08, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical…
IO Biotech Announces Abstract Accepted for Poster Presentation at ESMO Congress 2023
NEW YORK, Aug. 08, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical…
BioSyent Launches Inofolic® for Women with Polycystic Ovary Syndrome (PCOS)
Approximately 1.4 million Canadian women have PCOS, and this unique soft-gel capsule is approved to…
BioSyent Launches Inofolic® for Women with Polycystic Ovary Syndrome (PCOS)
Approximately 1.4 million Canadian women have PCOS, and this unique soft-gel capsule is approved to…
IN8bio Expands Capabilities with the Grand Opening of its Advanced Research and Development Facility
State-of-the-art facility will expand preclinical, clinical and process development capabilities to advance the company’s pipeline…